News for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings' financial position is stable for now, with about two years of cash runway. Click here to find out why CRBP stock is a Buy.

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”œCorbus” or the ”œCompany”), today announced that Yuval

Corbus Pharmaceuticals (CRBP) has appointed Rachelle Jacques to lead its Board of Directors, starting from May 15. Jacques takes over the role from Alan Holmer,

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. ( CRBP), a clinical-stage company focused on oncology and obesity, today

Oppenheimer has revised its price target for Corbus Pharmaceuticals (CRBP), reducing it from $60 to $56. Despite this adjustment, the firm continues to rate the

H.C. Wainwright has adjusted its price target for Corbus Pharmaceuticals (CRBP), dropping it to $40 from a previous $50, while maintaining a Buy rating on the s

In the first quarter of 2025, Corbus Pharmaceuticals (CRBP) made significant strides in its drug development pipeline. The company showcased promising Phase 1 r

Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumorsSAD/MAD study on sc

**media[615860]**

CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimon

CRB-701 Nectin-4 targeting ADC demonstrates encouraging results in Phase 1 Western study Fast Track Designation granted by FDA for CRB-701 to treat metastatic

NORWOOD, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”œCorbus” or the ”œCompany”), today announced that Yuva

**media[549724]**

On December 31, 2024, Orbimed Advisors LLC executed a significant transaction involving Corbus Pharmaceuticals Holdings Inc (CRBP). The firm reduced its holding

**media[540758]**

**media[537519]**

**media[526211]**

NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. ( CRBP) (”œCorbus” or the ”œCompany”), today announced that Yuva

**media[486994]**